Thomas Tillett | Chief Executive Officer
MBF Therapeutics

Thomas Tillett, Chief Executive Officer, MBF Therapeutics

Cofounder and CEO of MBF Therapeutics, an animal health company that is developing next generation gene based immunotherapies to treat cancer and infectious diseases in both companion animals and livestock. Tom is the founder and Executive Director of Sustained Acts, a Christian non-profit focusing on sustainable projects in Africa and serves on the Friends of Kijabe Hospital Board of Directors. Mr. Tillett was founder, and CEO of RHeoGene. As RheoGene CEO, he and his team created the RheoSwitch® Therapeutic System (RTS) that led to the first human clinical trial of a small molecule-induced gene regulation system. In 2007, he successfully completed the merger of RheoGene Inc. with Intrexon Corporation who has continued the development of RTS through a various clinical trials for cancer and other important therapeutic indications. In April, 2019 the FDA announced that the RheoSwitch Therapeutic System for glioma blastoma was approved for Fast Track designation. Mr. Tillett has served on the board of numerous non-profits including; University of North Carolina General Alumni Association, Impact Thrift Stores, Chelten Church Elder Board, and the American School of Paris. He was also elected to the Hatboro-Horsham Hall of Fame in 2017


Festival of Biologics Day 2 @ 15:20

Next generation COVID vaccine using T-Max Precision™ DNA vaccine platform

  • Provides longer term protection against a range of betacoronaviruses by eliciting a strong T cell response. 
  • Delivered intranasally to create a barrier to transmission in mucosal tissue
  • Relatively simple and lower cost manufacturing process and delivery system
last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers